Related Experiment Video
Updated: Apr 30, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
11.7K
Liver X receptor gene polymorphisms in tuberculosis: effect on susceptibility
Min Han1, Li Liang1, Li-Rong Liu1
1Shanghai Key Laboratory of Mycobacterium Tuberculosis, Shanghai Pulmonary Hospital Affiliated to Tongji University School of Medicine, Shanghai, P.R. China.
Plos One
|May 3, 2014
Summary
Single nucleotide polymorphisms (SNPs) in Liver X Receptors (LXRs) are associated with tuberculosis (TB) risk and clinical patterns. Specific LXR gene variants increase or decrease susceptibility to TB in the Chinese Han population.
Area of Science:
- Genetics
- Immunology
- Molecular Biology
Background:
- Liver X Receptors (LXRs), including LXRA and LXRB, are key regulators of lipid metabolism and innate immunity.
- LXRs play a critical role in controlling Mycobacterium tuberculosis (M.tb) infection, as evidenced by increased susceptibility in mice lacking these receptors.
Purpose of the Study:
- To investigate the association between single nucleotide polymorphisms (SNPs) in the LXRs genes and the risk of developing tuberculosis (TB).
- To explore the relationship between LXR gene variants and the clinical presentation of TB.
Main Methods:
- DNA sequencing of LXRs genes in 600 TB patients and 620 healthy controls from the Chinese Han population.
- Identification and analysis of eight common variants (SNPs) and their frequencies to determine associations with TB.
- Haplotype analysis to identify combinations of SNPs associated with TB risk and protection.
Main Results:
- Eight common SNPs in LXRs genes were identified, with several showing significant associations with TB risk.
- Specific alleles (G of rs1449627, T of rs1405655) were linked to increased TB risk.
- Other alleles in LXRA and LXRB were found to be protective against TB.
- Haplotype analysis revealed both risk (GGCG, TTCG) and protective (TTAT, CCAT, CATC) haplotypes.
- LXR SNPs were also associated with specific clinical patterns of TB disease.
Conclusions:
- The findings support a fundamental role for LXRs in genetic susceptibility to TB.
- LXR gene variations are linked to both the risk and diverse clinical manifestations of tuberculosis.
- Further research in larger, diverse populations is warranted to confirm these associations.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
189
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
01:27Pharmacogenetics of Drug Metabolism: Overview
194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
01:16Drug toxicity: Idiosyncratic Reactions
220
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
220